Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations

BioNTech SE (NASDAQ:BNTX) on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.

The COVID-19 vaccine maker reported sales of 1.19 billion euros, compared to 1.48 billion euros, beating consensus of 1.09 billion.

The revenue decrease was primarily driven by lower sales of the company’s COVID-19 vaccines due to reduced market demand.

In addition, write-downs by BioNTech’s collaboration partner Pfizer Inc (NYSE:PFE) significantly reduced the company’s gross profit share which negatively influenced its revenues.

Also Read: FDA Places Clinical Hold On BioNTech’s Early-Phase Trial For RNA-Based Malaria Vaccine

“From the very beginning, BioNTech’s vision has been to translate our science into survival and become an immunotherapy powerhouse. In 2024, we made significant progress towards our vision through important oncology pipeline advancements, including the initiation of global Phase 3 clinical trials for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 and key data updates from our mRNA cancer immunotherapy programs,” said BioNTech CEO Ugur Sahin. “We expect 2025 to be a data-rich year with multiple important updates from our priority programs…”

The cost of sales was 243.5 million euros, compared to 179.1 million euros a year ago, driven by COVID-19 vaccine sales, inventory write-downs, and scrapping.

Research and development expenses were 611.8 million euros compared to 577.8 million euros a year ago, mainly influenced by advancing clinical studies for the company’s late-stage oncology product candidates.

Guidance: BioNTech expects its 2025 revenues of 1.7 billion-2.2 billion euros compared to consensus of 2.57 billion euros and revenue phasing similar to 2024, primarily concentrated in the last three to four months, driving the full-year revenue figure.

BioNTech expects to continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology.

Price Action: BNTX stock is down 3.39% at $105.10 at the last check Monday.

Read Next:

• Europe-Based UCB’s Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

Image by Shutterstock